Cargando…

Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression

Immunotherapy has shown efficacy in relapsed multiple myeloma (MM). However, these therapies may depend on a functional tumor immune microenvironment (iTME) for their efficacy. Characterizing the evolution of the iTME over the disease course is necessary to optimize the timing of immunotherapies. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Visram, Alissa, Dasari, Surendra, Anderson, Emilie, Kumar, Shaji, Kourelis, Taxiarchis V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921408/ https://www.ncbi.nlm.nih.gov/pubmed/33649314 http://dx.doi.org/10.1038/s41408-021-00440-4

Ejemplares similares

Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies
por: Kourelis, Taxiarchis V., et al.
Publicado: (2019)

An atlas of the bone marrow bone proteome in patients with dysproteinemias
por: Ho, Matthew, et al.
Publicado: (2023)

An atlas of the bone marrow bone proteome in patients with dysproteinemias
por: Ho, Matthew, et al.
Publicado: (2023)

Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma
por: Pilcher, William, et al.
Publicado: (2023)

Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
por: Visram, Alissa, et al.
Publicado: (2021)

Outcomes after biochemical or clinical progression in patients with multiple myeloma
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
por: Uckun, Fatih M.
Publicado: (2021)

The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022)

Colon perforation in multiple myeloma patients – A complication of high‐dose steroid treatment
por: Vaxman, Iuliana, et al.
Publicado: (2020)

Proteomic profiling of sporadic late‐onset nemaline myopathy
por: Naddaf, Elie, et al.
Publicado: (2022)

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma
por: Paquin, Ashley, et al.
Publicado: (2020)

Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis
por: Yao, Lijun, et al.
Publicado: (2022)

Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients
por: Visram, Alissa, et al.
Publicado: (2021)

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
por: Goel, Utkarsh, et al.
Publicado: (2023)

Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database
por: McCurdy, Arleigh, et al.
Publicado: (2022)

CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma
por: Lewinsky, Hadas, et al.
Publicado: (2021)

Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma
por: Lv, Junqiang, et al.
Publicado: (2022)

The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant
por: Zanwar, Saurabh, et al.
Publicado: (2023)

Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

P-207: Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients
por: Rajkumar, S, et al.
Publicado: (2023)

N-Glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression
por: Dispenzieri, Angela, et al.
Publicado: (2020)

Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
por: Bansal, Radhika, et al.
Publicado: (2023)

The Impact of Re-induction Prior to Salvage Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2019)

Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
por: Zhang, Shijia, et al.
Publicado: (2020)

Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein–Barr Virus-Associated Malignancies
por: Zheng, Xueyi, et al.
Publicado: (2022)

Glutamine is essential for overcoming the immunosuppressive microenvironment in malignant salivary gland tumors
por: Cao, Shuting, et al.
Publicado: (2022)

Angioimmunoblastic T-cell lymphoma with predominant CD8+ tumor-infiltrating T-cells is a distinct immune pattern with an immunosuppressive microenvironment
por: Chen, Zihang, et al.
Publicado: (2022)

Immunosuppressive Microenvironment in Neuroblastoma
por: Pistoia, Vito, et al.
Publicado: (2013)

Comparable Outcomes using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2018)

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)
por: Ho, Matthew, et al.
Publicado: (2021)

SYST-27 INTERROGATION OF THE TUMOR IMMUNE MICROENVIRONMENT REVEALS DISTINCT IMMUNOSUPPRESSIVE LANDSCAPES IN GLIOBLASTOMA
por: Weng, Linqian, et al.
Publicado: (2023)

Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma
por: Baughn, Linda B., et al.
Publicado: (2023)

P812: PREDICTING HIGH-RISK DISEASE BIOLOGY USING ARTIFICIAL INTELLIGENCE BASED FDG PET/CT RADIOMICS IN NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Shreve, Jacob, et al.
Publicado: (2023)

New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib
por: Richardson, Paul G, et al.
Publicado: (2017)

Non‐cardiac biopsy sites with high frequency of transthyretin amyloidosis
por: Dasari, Surendra, et al.
Publicado: (2020)

The Immune Microenvironment in Multiple Myeloma: Friend or Foe?
por: Lopes, Raquel, et al.
Publicado: (2021)

Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
por: Schmidt, Walker M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hk1odgoglo1dbq1rjb6ji4dik8